僵直性脊椎炎市场:KOL的洞察

本报告提供全球僵直性脊椎炎市场相关调查，提供市场概要，以及已通过核准治疗方法，开发平台趋势，未来预测等资讯。

目录

摘要整理

治疗流程

调查目的

TNF抑制剂

• 市售疗法
  • Remicade(Infliximab，Janssen Biotech/Merck &Co.)，Enbrel(Etanercept，Pfizer/Amgen)，Simponi(gorimumabu，Janssen Biotech/Merck &Co.)，Humira(Adalimumab，AbbVie)，Cimzia(serutorizumabupegoru，UCB)(12)

IL-17抑制剂

• 已通过核准治疗方法
  • Cosentyx（苏金单抗，诺华）
  • Taltz（ixekizumab，礼来公司）
  • Bimzerx（bimekizumab、UCB）
• 管道处理
  • Izoquivep（Aceriline/Affibody）

JAK抑制剂

• 核准的治疗方法
  • Rinvoq（upadacitinib、艾伯维）
  • Xeljanz（託法替尼，辉瑞）
• 管道处理
  • Gyseleca（filgotinib，Galapagos NV）

其他作用机转

• 管道处理
  • Namilumab（安进/武田/Izana）

未来的治疗范例

附录

What does the future AS therapy landscape look like? Will the domination of anti-TNFs continue? How do KOLs assess the potential of anti-IL17 strategies? Could a re-evaluation of safety concerns see wider use of JAK inhibitors such as AbbVie's Rinvoq and Pfizer's Xeljanz? What pipeline therapies could bring new treatment options? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to KOL Bulletins.

Table of Contents

Executive summary (8)

Treatment algorithm (1)

Research objectives (5)

TNF inhibitors (12)

• Marketed therapies (12)
  • Remicade (infliximab; Janssen Biotech/Merck & Co.); Enbrel (etanercept; Pfizer/Amgen); Simponi (golimumab; Janssen Biotech/Merck & Co.); Humira (adalimumab; AbbVie); Cimzia (certolizumab pegol; UCB) (12)

IL-17 inhibitors (34)

• Approved therapies (28)
  • Cosentyx (secukinumab; Novartis) (10)
  • Taltz (ixekizumab; Lilly) (9)
  • Bimzelx (bimekizumab; UCB) (9)
• Pipeline drugs (6)
  • Izokibep (Acelyrin/Affibody) (6)

JAK inhibitors (18)

• Approved therapies (14)
  • Rinvoq (upadacitinib; AbbVie) (8)
  • Xeljanz (tofacitinib; Pfizer) (6)
• Pipeline therapies (4)
  • Jyseleca (filgotinib; Galapagos NV) (4)

Other mechanisms of action (6)

• Pipeline therapies (6)
  • Namilumab (Amgen/Takeda/Izana) (6)

Future treatment paradigm (11)

• Key insights summary (11)

Appendix (4)

• KOL details (4)
  • KOLs from North America (1)
  • KOLs from Europe (2)